Sijme Zeilemaker
About
Sijme Zeilemaker is from Leiden, South Holland, Netherlands. Sijme works in the following industries: "Pharmaceutical Manufacturing". Sijme is currently CEO at Immunetune. In Sijme's previous role as a Head of IR & Corporate Communication at Immunicum AB (IMMU), Sijme worked in until Jul 2021. Prior to joining Immunicum AB (IMMU), Sijme was a Chief Operating Officer at Immunicum AB (IMMU) and held the position of Chief Operating Officer. Prior to that, Sijme was a Senior Director Business Development at Immunicum AB (IMMU) from Mar 2017 to Dec 2019. Sijme started working as Director Business Development at InteRNA Technologies BV in Utrecht Area, Netherlands in Nov 2015. From May 2015 to Jan 2017, Sijme was Head of Business at 2-BBB Medicines BV. Prior to that, Sijme was a Business Development Manager at BBB Therapeutics from Oct 2013 to Mar 2015. Sijme started working as Business Development Associate at BBB Therapeutics in Jan 2012.
You can find Sijme Zeilemaker's email at finalscout.com. FinalScout is a professional database with business professional profiles and company profiles.
Sijme Zeilemaker's current jobs
Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free generation of personalized cancer vaccines encoding multiple (neo-)antigens in linear synthetic DNA with improved immunogenicity through its unique PyroVant™ adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and is finalizing its preclinical package with the aim to initiate clinical studies in 2022. Immunetune’s pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting conserved proteins across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.